
Xenobiotica p. 501 - 510 (1995)
Update date:2022-07-29
Topics:
Fujimaki
Hosokami
Ono
14C-Ecabapide, 3-[[[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl]methyl]amino-N-methyl[14 C]benzamide, was dosed orally to rat (100 mg/kg). Within 48 h after dosing, 36.7 ± 5.4 and 55.7 ± 11.8% of the administered radioactivity was recovered from urine and faeces respectively. The unchanged drug was the major compound excreted in the urine and accounted for 37% of the urinary radioactivity. Seven urinary metabolites were purified by preparative hplc and their structures were elucidated by mass and 1H-nmr spectrometry. The major metabolic pathway of ecabapide was found to be the formation of 3-amino-N-methylbenzamide produced by N-dealkylation of the secondary amine at the 3-position of the benzamide moiety followed by acetylation. Further metabolic pathways of the N-methylbenzamide moiety were N-demethylation via the carbinolamine derivatives, and/or aromatic hydroxylation followed by glucuronidation.
View MoreNantong LiKai Chemical Co.,Ltd
Contact:+86-513-89068669
Address:Jincheng Science Park
website:http://www.tcfinechem.com/
Contact:18681346930
Address:baifu town,whou district
website:http://www.cartoonchem.com/
Contact:+86-25-58074918
Address:Room 2109, RuiHua Business Center,315 South ZhongShan Road, Nanjing 210001, China
Contact:86-21-57725962
Address:shanghai
Contact:86-791-86629460
Address:1-6F, 118 Xinzhou road, Nanchang, Jiangxi, China
Doi:10.1039/dt9960002693
(1996)Doi:10.1021/acs.jmedchem.5b01008
(2015)Doi:10.1016/S0031-9422(00)82958-1
(1967)Doi:10.1016/0040-4039(96)00904-5
(1996)Doi:10.1016/0040-4020(96)00549-2
(1996)Doi:10.1016/S0040-4020(97)00816-8
(1997)